AI-based Clinical Trial Solution Providers Global Market Report 2024

The ai-based clinical trial solution providers market size has grown exponentially in recent years. It will grow from $2 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 23.7%. Historical growth can be attributed to increased complexity in clinical trials, the growing volume of clinical trial data, challenges related to regulatory compliance, demands in drug discovery and development, and trends in personalized medicine.

The ai-based clinical trial solution providers market size is expected to see exponential growth in the next few years. It will grow to $5.65 billion in 2028 at a compound annual growth rate (CAGR) of 23%. The forecasted growth can be attributed to integration with real-world evidence (RWE), advancements in natural language processing (NLP), adoption of decentralized clinical trials, expansion of therapeutic areas, and enhanced predictive analytics. Major trends in the forecast period include collaboration with biotech and pharma companies, patient-centric approaches, predictive analytics for trial design, integration of real-world evidence, and the utilization of blockchain for data security.

The growing adoption of AI technology is anticipated to drive the expansion of the market for AI-based clinical trial solution providers in the future. AI, or artificial intelligence, involves the development of computer systems or software capable of performing tasks typically requiring human intelligence. Clinical trial solution providers are increasingly leveraging AI technology to enhance efficiency, accuracy, and innovation throughout various stages of the clinical trial process, leading to improved patient outcomes and advancements in medical research. For example, in May 2022, The International Business Machines Corporation (IBM), a US-based technology corporation, reported a significant global increase in the adoption rate of AI, with a 35% rise compared to the previous year. Moreover, around 35% of organizations reported adopting AI in their company, while 42% are considering its adoption, and two-thirds (66%) are either currently implementing or planning to utilize AI to achieve their sustainability goals. Consequently, the rising adoption of AI technology is fueling the growth of the AI-based clinical trial solution provider market.

Leading companies in the AI-based clinical trial solution providers market are actively developing innovative technological solutions, such as the Saama AI-driven data platform, to expedite clinical development and reinforce their market position. An AI-driven data platform utilizes artificial intelligence (AI) and machine learning (ML) to automate and enhance various data management and analysis processes. For instance, in June 2023, Saama Technologies, Inc., a US-based software company, unveiled the Saama AI-driven data platform. This platform optimizes clinical trial processes by centralizing and standardizing data, providing real-time insights into trial operations, financials, and patient data. By employing AI and advanced analytics, the platform automates tasks, boosts productivity, and delivers profound insights into patient behaviors. Through SaaS solutions such as data hubs, operational insights, patient insights, S2S, and SDQ, Saama empowers AI-based clinical trial solution providers to maximize efficiency, accuracy, and effectiveness while reducing manual, resource-intensive activities to streamline clinical trials.

In September 2023, Florence Healthcare, a US-based healthcare company, acquired VersaTrial Inc. for an undisclosed sum. This acquisition brings together two pioneering entities in the eClinical space, combining their complementary strengths to deliver a more robust solution for research sites, CROs, and sponsors. VersaTrial Inc. is a US-based provider of AI-based clinical trial solutions.

Major companies operating in the ai-based clinical trial solution providers market report are International Business Machines Corporation, AstraZeneca, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., BenevolentAI, Charles River Laboratories, Flatiron Health, Saama Technologies Inc., CytoReason, Median Technologies SAS, Concentro Health AI., AiCure, LLC, DEEP LENS AI Inc., GNS Healthcare, Inc., Ardigen, Koneksa Health Inc., Unlearn.AI Inc., PathAI Inc., Deep 6 AI Inc., Intelligencia Inc., Exscientia, Prometheus Biosciences, Inc., Renalytix AI plc, BioAge Labs Inc., Mendel Health Inc.

North America was the largest region in the AI-based clinical trial solution providers market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ai-based clinical trial solution providers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the AI-based clinical trial solution provider market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The AI-based clinical trial solution provider market consists of revenues earned by entities by providing services such as data analysis, patient recruitment and retention, drug trial process optimization, and predictive analytics for clinical outcomes. The AI-based clinical trial solution providers market also includes sales of mobile devices, medical devices and servers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

AI-based clinical trial solution providers are entities that offer technological solutions utilizing artificial intelligence (AI) for different facets of the clinical trial process in the healthcare and pharmaceutical sectors. These solutions aim to improve the efficiency, accuracy, and overall effectiveness of clinical trials, ranging from study design and patient recruitment to data analysis and regulatory compliance.

The main types of clinical trial phases addressed by AI-based clinical trial solution providers include phase I, phase II, and phase III. Phase I represents the initial stage of clinical trials conducted during the development of a new medical intervention, such as a drug, vaccine, or medical device. These solutions cater to various therapeutic applications, including oncology, cardiovascular diseases, neurological conditions, metabolic disorders, infectious diseases, and others. They are utilized by end-users such as pharmaceutical companies, academia, and other stakeholders involved in clinical research.

The AI-based clinical trial solution providers market research report is one of a series of new reports that provides AI-based clinical trial solution providers market statistics, including AI-based clinical trial solution providers industry global market size, regional shares, competitors with a AI-based clinical trial solution providers market share, detailed AI-based clinical trial solution providers market segments, market trends and opportunities, and any further data you may need to thrive in the AI-based clinical trial solution providers industry. This AI-based clinical trial solution providers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.